GlassScriptPhysician profile
Daniel De Los Heros
NPI 1578971032
$796.97
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $328 · 2021: $159 · 2022: $15.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.27 | 2019-2021 | |
| Therapeuticsmd, INC. | $129.96 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $67.60 | 2019-2021 | |
| Coopersurgical, INC. | $44.22 | 2019-2021 | |
| Millicent US INC | $43.97 | 2020-2021 | |
| Minerva Surgical, INC | $30.86 | 2020-2022 | |
| Hologic Sales and Service, LLC | $28.18 | 2020 | |
| Roche Diagnostics Corporation | $25.83 | 2019 | |
| Agile Therapeutics, INC. | $22.41 | 2021 | |
| Ethicon US, LLC | $21.43 | 2021 | |
| Sage Therapeutics, LLC | $18.68 | 2019 | |
| Evofem Biosciences, INC. | $18.12 | 2021 | |
| Glaxosmithkline, LLC. | $17.97 | 2019 | |
| Amgen INC. | $15.42 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.15 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.94 | 2020 | |
| Pfizer INC. | $14.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel De Los Heros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.